Zhejiang Longchuan Biomedical Technology

Zhejiang Longchuan Biomedical Technology is a clinical-stage biotechnology company headquartered in Hangzhou, China, specializing in the development of next-generation biologics. The company focuses on oncology and metabolic disorders, utilizing a proprietary protein engineering platform to design multi-target fusion proteins and high-affinity antibodies. Its lead program, LC001, is a bifunctional fusion protein targeting PD-L1 and TGF-β designed to overcome resistance to traditional checkpoint inhibitors. Longchuan Biomedical maintains a robust pipeline of candidates including anti-CD47 antibodies and GLP-1 receptor agonists. The firm is dedicated to providing innovative and affordable therapeutic solutions for patients worldwide.